Patents Examined by Taylor V. Oh
  • Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
    Patent number: 11168071
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a triazole-methyl-piperidinyl-pyrolyl-propenone structure which function as modulators of shared epitope (SE)—calreticulin (CRT) binding and/or interaction, and their use as therapeutics for the treatment of immunoregulatory abnormalities (e.g., autoimmune diseases, inflammatory diseases (e.g., chronic inflammatory disease), and bone erosive diseases) by selectively inhibiting SE-CRT interactions and/or signal transduction pathways commonly overactive or dysregulated in arthritic and/or other diseases or conditions.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: November 9, 2021
    Assignee: The Regents of the University of Michigan
    Inventors: Joseph Holoshitz, Andrew White
  • Composition for activating sympathetic nerve
    Patent number: 11147791
    Abstract: An object of the present invention is to provide a novel composition for use in activating a sympathetic nerve. The present invention provides a composition for use in activating a sympathetic nerve, comprising a polyphenol as an active ingredient. The polyphenol comprises 25% by mass or more of monomeric to tetrameric polyphenols, and the monomeric to tetrameric polyphenols include at least catechin, epicatechin, procyanidin B2, procyanidin B5, procyanidin C1 and cinnamtannin A2.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: October 19, 2021
    Inventors: Kazuji Tamura, Hiroki Ohara
  • Pharmaceutical composition containing DUSP1 inhibitor
    Patent number: 11147807
    Abstract: The present invention relates to a pharmaceutical composition comprising a DUSP1 inhibitor. The pharmaceutical composition comprising the DUSP1 inhibitor according to the present invention can solve the problems of inhibitors that target the active site because it inhibits DUSP1 by an allosteric inhibitory mechanism, and is effective for preventing or treating diseases involving DUSP1 enzymes, for example, a cancer such as a liver cancer, a breast cancer and a pancreatic cancer, a hepatitis C, and a depression. In particular, the DUSP1 inhibitor according to the present invention is very effective in treating a depression because it directly acts on neuronal growth.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: October 19, 2021
    Assignees: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Seong Eon Ryu, Tae Hyun Park, Kwang Hwan Lee, Ju Seop Kang, Shin Hee Kim, Kyoung Tae Nam, Hyeon Kyu Lee
  • Inhibitors of microbially induced amyloid
    Patent number: 11147792
    Abstract: The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: October 19, 2021
    Assignees: AXIAL THERAPEUTICS, INC., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Timothy Sampson, Sarkis Mazmanian, Anthony Stewart Campbell
  • Intermediate for preparing eribulin mesylate and process for preparing the same
    Patent number: 11142509
    Abstract: The present invention relates to a process for preparing a compound of formula (6) which is an intermediate for the preparation of eribulin mesylate with high yields and high purity, and an intermediate therefor.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 12, 2021
    Assignee: YONSUNG FINE CHEMICAL CO., LTD.
    Inventors: Hyunik Shin, Keeyoung Lee, Changyoung Oh
  • Method of treatment
    Patent number: 11141400
    Abstract: One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least ½ hour prior to administration, no food at least 1 hour prior to administration, no food at least 1½ hours prior to administration, no food at least 2 hours prior to administration, no food at least 2½ hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: October 12, 2021
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
  • Compositions and methods for inhibiting protein kinases
    Patent number: 11135209
    Abstract: Identified compounds demonstrate protein kinase inhibitory activity and inhibition of dependent cell signaling pathways, such as NOD2 cell signaling. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 5, 2021
    Assignees: University of Houston System, Trustees of Tufts College
    Inventors: Gregory Cuny, Chalada Suebsuwong, Alexei Degterev
  • Carbonate derivative production method
    Patent number: 11130728
    Abstract: The objective of the present invention is to provide a method for producing a carbonate derivative in a safe and efficient manner. The method for producing a carbonate derivative according to the present invention is characterized in comprising irradiating light on a composition containing a C1-4 halogenated hydrocarbon having one or more kinds of halogen atoms selected from the group consisting of a chlorine atom, a bromine atom and an iodine atom, a nucleophilic functional group-containing compound and the specific base in the presence of oxygen.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: September 28, 2021
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventor: Akihiko Tsuda
  • Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
    Patent number: 11130755
    Abstract: The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: September 28, 2021
    Assignee: SANOFI
    Inventors: Dirk Gretzke, Olaf Ritzeler, Uwe Heinelt, Volkmar Wehner, Friedemann Schmidt
  • Catalysts utilizing carbon dioxide for the epoxidation of olefins
    Patent number: 11123712
    Abstract: The present disclosure provides mixed molybdenum oxide catalysts, methods for preparing epoxides from olefins and CO2 using them, and methods of making the mixed molybdenum oxide catalysts by impregnation or co-precipitation. In a preferred embodiment, the mixed molybdenum oxide catalysts are silver/molybdenum oxide catalysts, ruthenium/molybdenum oxide catalysts, or a combination thereof.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: September 21, 2021
    Assignee: RESEARCH TRIANGLE INSTITUTE
    Inventors: Marty Lail, Paul Mobley, Jonathan Peters, Sree Nandita Akunuri, Joshua J. Hlebak
  • Use of daphnetin in improving function of aortic endothelial cell
    Patent number: 11110075
    Abstract: The disclosure relates to a pharmaceutical composition including daphnetin, a method for improving aortic endothelial cell function, and use of daphnetin in preparation of a medicine for improving aortic endothelial cell function. The daphnetin is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The daphnetin is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: September 7, 2021
    Assignee: XI'AN JIAOTONG UNIVERSITY
    Inventors: Jian-Gang Long, Xu-Yun Liu, Jian-Kang Liu
  • Method for purifying and removing color of FDCA
    Patent number: 11104656
    Abstract: The invention is based on the finding that when conducting crystallization of FDCA at high temperatures, the formation of significant amounts of colored byproduct can be reduced or even avoided when the FDCA mixture is kept at temperatures above 100° C. for less than 15 minutes. This is achieved by conducting the crystallization process in a continuous reactor. Accordingly, the method comprises the steps of feeding a mixture comprising undissolved FDCA and a solvent to a reactor; and dissolving FDCA by superheating the mixture in the reactor to a temperature of at least 130° C.; and crystallizing FDCA by cooling the mixture in the reactor, wherein the reactor is a continuous reactor and the residence time in the reactor zone wherein the FDCA mixture has a temperature above 100° C. is less than 15 minutes.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: August 31, 2021
    Assignee: Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO
    Inventors: Carol Andrea Roa Engel, Johannes Van Der Meer, Leonard Ferdinand Gerard Geers, Marc Crockatt
  • Energy recovery in a method for preparing 1,3,5-trioxane
    Patent number: 11097202
    Abstract: The present invention relates to a process for energy recovery in a process for the preparation of 1,3,5-trioxane.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: August 24, 2021
    Assignees: BASF SE, Kolon Plastics Inc.
    Inventors: Achim Stammer, Thomas Heitz, Marvin Kramp, JongMoon Kim, In-Gi Cho, Jin-Sang Choi, Sang-Yup Lee
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 11098041
    Abstract: Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: August 24, 2021
    Assignee: Merck Patent GmbH
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • Inhibitors of influenza virus replication and uses thereof
    Patent number: 11098042
    Abstract: Provided herein is inhibitors of influenza virus replication and uses thereof. Specifically, provided herein a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: August 24, 2021
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Qingyun Ren, Changhua Tang, Junjun Yin, Kai Yi, Yibo Lei, Yejun Wang, Yingjun Zhang
  • Method for preparing alkylamines
    Patent number: 11084777
    Abstract: The present invention relates to a method for preparing alkylamines using carbon monoxide and the use of this method in the manufacturing of vitamins, pharmaceutical products, adhesives, acrylic fibres and synthetic leathers, pesticides, surfactants, detergents and fertilisers. It also relates to a method for manufacturing vitamins, pharmaceutical products, adhesives, acrylic fibres, synthetic leathers, pesticides, surfactants, detergents and fertilisers, comprising a step of preparing alkylamines by the method according to the invention. The present invention further relates to a method for preparing marked alkylamines and uses thereof.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: August 10, 2021
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Solène Savourey, Thibault Cantat, Tawfiq Nasr-Allah
  • 4H-pyrrolopyridine compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide
    Patent number: 11083198
    Abstract: In crop production in the fields of agriculture, horticulture and the like, the damage caused by insect pests etc. is still immense, and insect pests resistant to existing insecticides have emerged. Under such circumstances, the development of novel agricultural and horticultural insecticides is desired. The present invention provides an agricultural and horticultural insecticide comprising a 4H-pyrrolopyridine compound represented by the general formula (1): {wherein R1 represents a halogen atom, R2 and R3 each represent a haloalkyl group, Q represents Q-A, Q-B or Q-C, X represents a nitrogen atom, R4 and R7 each represent a hydrogen atom, R2 and R3 each represent a halogen atom, a haloalkyl group or a substituted phenyl group, and m represents 2} or a salt thereof as an active ingredient; and a method for using the insecticide.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: August 10, 2021
    Assignee: Nihon Nohyaku Co., Ltd.
    Inventors: Ikki Yonemura, Yusuke Sano, Naoto Shimizu, Akihiro Miyasaka, Akiyuki Suwa, Shunpei Fujie, Ryosuke Tanaka
  • Integrated methods for chemical synthesis
    Patent number: 11078172
    Abstract: The integrated processes herein provide improved carbon efficiency for processes based on coal or biomass gasification or steam methane reforming. Provided are also ethylene oxide carbonylation products such as beta-propiolactone and succinic anhydride having a bio-based content between 0% and 100%, and methods for producing and analyzing the same.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: August 3, 2021
    Assignee: Novomer, Inc.
    Inventors: Sadesh H. Sookraj, Michael A. Slowik
  • Tableted medicinal composition comprising nalfurafine
    Patent number: 11071734
    Abstract: A tableted pharmaceutical composition contains nalfurafine or a pharmaceutically acceptable acid addition salt thereof and is excellent in formability and quality control of related substances. The tableted pharmaceutical composition includes nalfurafine or a pharmaceutically acceptable acid addition salt thereof, a binder component, and a carrier, wherein the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof is contained in an amount of 0.1 to 10 ?g, and the weight of the above mentioned binder component is 100,000 to 2,000,000 weight % based on the weight of the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof and 5 to 20 weight % based on the total weight of the resulting pharmaceutical composition, or 20,000 to 500,000 weight % and 1 to 5 weight % based on the total weight of the resulting pharmaceutical composition.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: July 27, 2021
    Assignee: Toray Industries, Inc.
    Inventors: Satoshi Minakami, Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi
  • Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
    Patent number: 11065258
    Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: July 20, 2021
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Alison M. Taylor